Logo image of EVA

ENVIVA INC (EVA) Stock Fundamental Analysis

NYSE:EVA - New York Stock Exchange, Inc. - US29415B1035 - Common Stock - Currency: USD

0.4198  +0.01 (+2.22%)

Fundamental Rating

2

Overall EVA gets a fundamental rating of 2 out of 10. We evaluated EVA against 213 industry peers in the Oil, Gas & Consumable Fuels industry. EVA may be in some trouble as it scores bad on both profitability and health. EVA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

EVA had negative earnings in the past year.
EVA had a negative operating cash flow in the past year.
In multiple years EVA reported negative net income over the last 5 years.
Of the past 5 years EVA 4 years had a positive operating cash flow.
EVA Yearly Net Income VS EBIT VS OCF VS FCFEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M -200M -300M

1.2 Ratios

EVA has a worse Return On Assets (-11.74%) than 89.00% of its industry peers.
EVA has a Return On Equity of -109.62%. This is amonst the worse of the industry: EVA underperforms 93.30% of its industry peers.
Industry RankSector Rank
ROA -11.74%
ROE -109.62%
ROIC N/A
ROA(3y)-3.96%
ROA(5y)-2.25%
ROE(3y)-28.14%
ROE(5y)-16.14%
ROIC(3y)N/A
ROIC(5y)N/A
EVA Yearly ROA, ROE, ROICEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -20 -40

1.3 Margins

The Gross Margin of EVA (1.44%) is worse than 84.21% of its industry peers.
EVA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.71%
GM growth 5Y-15.21%
EVA Yearly Profit, Operating, Gross MarginsEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 10 -10

2

2. Health

2.1 Basic Checks

EVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVA has more shares outstanding
The debt/assets ratio for EVA has been reduced compared to a year ago.
EVA Yearly Shares OutstandingEVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
EVA Yearly Total Debt VS Total AssetsEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of 0.16, we must say that EVA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EVA (0.16) is worse than 71.29% of its industry peers.
EVA has a Debt/Equity ratio of 5.83. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of EVA (5.83) is worse than 93.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.83
Debt/FCF N/A
Altman-Z 0.16
ROIC/WACCN/A
WACC3.08%
EVA Yearly LT Debt VS Equity VS FCFEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M 1B 1.5B

2.3 Liquidity

EVA has a Current Ratio of 1.42. This is a normal value and indicates that EVA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.42, EVA is in line with its industry, outperforming 59.33% of the companies in the same industry.
EVA has a Quick Ratio of 1.06. This is a normal value and indicates that EVA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EVA (1.06) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.06
EVA Yearly Current Assets VS Current LiabilitesEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

3

3. Growth

3.1 Past

The earnings per share for EVA have decreased strongly by -68.50% in the last year.
EVA shows a decrease in Revenue. In the last year, the revenue decreased by -0.20%.
The Revenue has been growing by 15.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-68.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-936.36%
Revenue 1Y (TTM)-0.2%
Revenue growth 3Y16.93%
Revenue growth 5Y15.04%
Sales Q2Q%-1.55%

3.2 Future

The Earnings Per Share is expected to decrease by -3.17% on average over the next years.
EVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.60% yearly.
EPS Next Y-148.2%
EPS Next 2Y6.01%
EPS Next 3Y14.13%
EPS Next 5Y-3.17%
Revenue Next Year-6.05%
Revenue Next 2Y1.19%
Revenue Next 3Y11.72%
Revenue Next 5Y10.6%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EVA Yearly Revenue VS EstimatesEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
EVA Yearly EPS VS EstimatesEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -2 -4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVA Price Earnings VS Forward Price EarningsEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EVA is valued a bit more expensive than 79.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 94.98
EVA Per share dataEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

EVA's earnings are expected to grow with 14.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.01%
EPS Next 3Y14.13%

0

5. Dividend

5.1 Amount

No dividends for EVA!.
Industry RankSector Rank
Dividend Yield N/A

ENVIVA INC

NYSE:EVA (10/3/2024, 8:11:14 PM)

0.4198

+0.01 (+2.22%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)09-13 2024-09-13/amc
Earnings (Next)10-30 2024-10-30/amc
Inst Owners57.12%
Inst Owner Change-95.37%
Ins Owners21.27%
Ins Owner Change0%
Market Cap31.43M
Analysts45
Price Target4.08 (871.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend3.3
Dividend Growth(5Y)6.05%
DP-32.32%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-143.34%
Min EPS beat(2)-288.14%
Max EPS beat(2)1.47%
EPS beat(4)1
Avg EPS beat(4)-199.08%
Min EPS beat(4)-288.14%
Max EPS beat(4)1.47%
EPS beat(8)1
Avg EPS beat(8)-988.96%
EPS beat(12)2
Avg EPS beat(12)-666.21%
EPS beat(16)4
Avg EPS beat(16)-503.85%
Revenue beat(2)0
Avg Revenue beat(2)-5.65%
Min Revenue beat(2)-9.42%
Max Revenue beat(2)-1.88%
Revenue beat(4)0
Avg Revenue beat(4)-16.16%
Min Revenue beat(4)-43.89%
Max Revenue beat(4)-1.88%
Revenue beat(8)1
Avg Revenue beat(8)-12.45%
Revenue beat(12)2
Avg Revenue beat(12)-9.32%
Revenue beat(16)3
Avg Revenue beat(16)-8.99%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.15
EV/EBITDA 94.98
EPS(TTM)-4.23
EYN/A
EPS(NY)-1.58
Fwd EYN/A
FCF(TTM)-4.42
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS15.11
BVpS4.14
TBVpS2.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.74%
ROE -109.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.44%
FCFM N/A
ROA(3y)-3.96%
ROA(5y)-2.25%
ROE(3y)-28.14%
ROE(5y)-16.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.71%
GM growth 5Y-15.21%
F-Score3
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 5.83
Debt/FCF N/A
Debt/EBITDA 111.49
Cap/Depr 207.35%
Cap/Sales 23.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.06
Altman-Z 0.16
F-Score3
WACC3.08%
ROIC/WACCN/A
Cap/Depr(3y)226.42%
Cap/Depr(5y)192.31%
Cap/Sales(3y)21.08%
Cap/Sales(5y)16.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-68.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-936.36%
EPS Next Y-148.2%
EPS Next 2Y6.01%
EPS Next 3Y14.13%
EPS Next 5Y-3.17%
Revenue 1Y (TTM)-0.2%
Revenue growth 3Y16.93%
Revenue growth 5Y15.04%
Sales Q2Q%-1.55%
Revenue Next Year-6.05%
Revenue Next 2Y1.19%
Revenue Next 3Y11.72%
Revenue Next 5Y10.6%
EBIT growth 1Y43.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.49%
EBIT Next 3Y202.11%
EBIT Next 5Y141.9%
FCF growth 1Y-88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-167.89%
OCF growth 3YN/A
OCF growth 5YN/A